Over the past few years, the mutational status of the immunoglobulin heavy chain variable region (IGHV) genes has proved to be a major determinant in the prognostic evaluation of chronic lymphocytic leukemia (CLL). 1 As this criterion becomes more frequently used for patient selection during clinical trials, its accurate determination is critical. In this regard, several technical recommendations have recently been proposed by an international panel of investigators, which should help to reach a better methodological standardization and obtain reliable sequences.
The correct determination of the mutational status strictly depends on the comparison of the nucleotide sequence of the clonal IGHV gene rearrangement expressed by the patient's leukemic cells with that of the closest germline counterpart. Although in theory this should be performed with the patient's germline DNA sequence from non-leukemic cells, it is a common practice to use public web-based databases, which provide a repository of the germline IGHV sequences along with various bioinformatic tools for sequence alignment. Several of these reference databases are available and include VBASE, 2 GenBank/IgBLAST 3 and the international ImMunoGeneTics information system s (IMGT). 4 They differ in terms of the type of software employed, the criteria used to delineate the complementarity determining regions (CDR) and framework regions, as well as the extent of natural IGHV polymorphism taken into account. For all these reasons, discrepancies among the different databases occur when analyzing IGHV sequences, although it is not known to what extent they may affect the correct interpretation of the IGHV mutational status in CLL.
IMGT consists of sequence, genome and structure databases, Web resources and interactive tools. It is the most comprehensive and more regularly updated database in terms of immunoglobulin gene polymorphisms/alleles. A comparison between IMGT and VBASE has previously been reported, 5 but the observed discrepancies were in part explainable by the fact that the latter has ceased to be updated since 1997. GenBank/IgBLAST was developed to facilitate analysis of the immunoglobulin V region sequences listed in GenBank, and it is widely used as it utilizes BLAST, the most familiar algorithm for finding similarities between biological sequences. Until very recently, the GenBank/IgBlast database included only Ig germline genes. In August 2007, it was updated including all the human Ig germline genes/alleles as defined by IMGT, while still providing the option to search the old database version. In the present study, we demonstrate that determination of IGHV mutational status in CLL is significantly more reliable when based on a comprehensive data set of Ig genes/alleles, such as the one provided by IMGT and the new, updated version of GenBank/IgBlast.
In April 2007, a large collection of 1437 IGHV sequences from patients with CLL, obtained from seven institutions in five European countries, were collected and aligned with their closest germline counterpart using the IMGT database and what now represents the 'old' version of the GenBank/IgBlast database. These sequences were obtained as previously described. 6 Only functional sequences, and those without any insertion or deletion events, were taken into consideration. Following the European consensus recommendations, 1 IGHV sequences extended from the first nucleotide in framework region 1 downstream of the primer used for amplification to the 95/96/97 codon in Kabat nomenclature (that is CDR3-IMGT codon 105/106/107) depending on exonuclease trimming, with the last codon having at least two consecutive germline nucleotides.
Remarkably, a similar degree of identity was found in only 63% of cases (Table 1) . Thus in about one-third of the cases from this series, a different percentage of identity was given by the two databases, a proportion much higher than reported in a previous study (7.5%). 7 In 306 cases (21%) this discrepancy was below 0.5%, and in 31 cases (2%) between 0.5 and 1%. However, it was equal or above 1% in 197 cases (14%), and could be as high as 8.2% in rare instances. Within this group of highly discordant cases (difference in the percentage of identity to the closest germline gene X1%), 19 IGHV genes were represented, with IGHV1-3, IGHV3-30, IGHV4-4 and IGHV3-48 being the genes most frequently subject to discrepancy ( Figure 1 ). Careful examination of the results obtained from both databases showed that IMGT provided additional alleles or genes not listed in the old version of the GenBank/IgBLAST database (Table 2) . Thus, allelic variations of 12 different IGHV genes were counted as somatic mutations by the old version of GenBank/IgBLAST as its reference data set did not include the relevant alleles. For example, alleles n02, n04 and n09 of IGHV1-69 were not included in the GenBank/IgBLAST old reference dataset, which instead used allele n06 for comparison, leading to an underestimation of the percentage of identity to germ line by 1.3-2%.
In the case of nine other genes, the old version of GenBank/ IgBLAST assigned and compared the CLL sequence to a different IGHV gene. This may be explained by the fact that some alleles of a certain gene were misidentified for another gene, for example allele n01 or n04 of IGHV3-66 which were considered as IGHV3-53 in GenBank/IgBLAST. For this gene, GenBank/ IgBLAST has recorded only IGHV3-66 allele n03, which has four nucleotides that are different from alleles n01 and n04. Furthermore, there were also IGHV genes such as IGHV4b, IGHV5a, IGHV7-4-1, which were simply absent from the old GenBank/IgBLAST reference dataset, thus leading to a high degree of discrepancy (2.4-8.2%).
Of clinical importance, based on a 98% cut-off, which is used by the vast majority of studies to make the clinically relevant distinction between mutated and unmutated cases, 8 52 cases (4%) of our cohort had a different clinical mutational status according to the database used and consequently would have been assigned to an opposite prognostic category. They were considered as unmutated if the comparison was performed with IMGT, whereas they appeared to be mutated if the old version of GenBank/IgBLAST served as reference. Clinical data were available for 28 of these patients, of which 25 (89.3%) had a progressive disease necessitating therapy. Although the concordance between the mutational status and the clinical outcome is not absolute, these data strongly support the possibility of these patients having indeed an unmutated status.
In conclusion, we show that the IMGT reference dataset of the human IGHV germline repertoire, including all so far identified allelic variants, offers a more accurate evaluation of IGHV mutational status in CLL. Investigators who have so far relied on the old version of the GenBank/ IgBlast database should re-run all their sequences against the IMGT repository of human germline genes/alleles, using the IMGT database or the new version of GenBank/ IgBlast. Based on the evidence presented in this study, the use of the old version of GenBank/IgBlast for IGHV gene analysis in CLL should be discouraged and clinicians should re-evaluate old data. Frequency of the immunoglobulin heavy chain variable region genes displaying X1% discrepancy in evaluation of homology to germline counterpart using the international ImMunoGeneTics information system or GenBank/IgBLAST databases. The white bars indicate the percentage of cases among the 197 chronic lymphocytic leukemia (CLL) sequences with X1% homology difference between the two databases. The black bars indicate the percentage of cases among the 52 CLL patients who had discordant mutational status (based on the 98% cutoff value) with the two databases.
Table 2
Reasons for database discrepancies in IGHV assignment Abbreviations: IMGT, international ImMunoGeneTics information system; IGHV, immunoglobulin heavy chain variable region. Reply to 'Rituximab in CD20 positive multiple myeloma' by P Moreau et al. We read with interest the Phase II study of Moreau et al., Although the authors did not observe a major impact of rituximab therapy in MM, we would like to draw attention to one patient in their study with 100% CD20 expression who experienced an ongoing 18 month minor response, in contrast to the other patients.
There exists a subset of myeloma with a primary IgH translocation involving t(11;14) which is associated more commonly with CD20 expression. Notably, one series demonstrated that 10 out of 12 patients (83%) with CD20 þ MM had t(11;14) in contrast to 5 out of 54 patients with CD20À MM (9%).
2
Clonogenic cells are important in the pathogenesis of MM, and have been described to be CD20 þ .
3 If so, CD20 þ cells represent an attractive target in halting the disease progression. While there have been relatively few reported responses to rituximab in MM, we report notable clinical benefit and improvement in M-spike with rituximab in a patient with newly diagnosed MM who had 90% CD20 þ bone marrow plasma cells (BMPCs) and t(11;14)(q13;q32) by fluorescent in situ hybridization.
Rituximab was used as a single agent in a 67-year-old patient with ISS stage I MM who had presented with exercise intolerance, fatigue and anemia. He had a serum M-spike of 4.5 gm/dl with an IgA level of 4750 gm/dl. The bone marrow revealed 42% plasma cells, 90% of which were strongly CD20 þ (Figure 1 ). Fluorescent in situ hybridization revealed t(11;14) (q13;32) in 60% of BMPCs correlating with the presence of cyclin D1 on immunohistochemical staining (Figure 2) . 4 Five weeks after completion of four weekly cycles of rituximab (375 mg/m 2 ), a decline in serum M-spike and IgA level to a nadir of 3.3 g/dl and 2990 gm/dl, respectively, was noted (Figure 3) . The therapy was well tolerated except for transient nausea, fever and rigors with the first infusion only. A second course of weekly rituximab Â 4 was initiated, followed by maintenance therapy once every other month. He became asymptomatic and his disease stabilized for 12 months. Subsequent bone marrow studies demonstrated an expanding clone of BMPCs with significantly reduced CD20 expression. Other regimens were therefore offered to him. His MM, however, has progressed through successive therapeutic interventions. As was the case in our patient, stable disease was achieved in all seven of the stage 1 (never treated) patients in the authors' study for 4-15 months. This distinction highlights an important consideration for Histogram of CD20 þ bone marrow plasma cells. Flow cytometry histogram depicts that 90% of CD38 þ bone marrow plasma cells are also CD20 þ .
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